The Global Health Body Sounds Alert Over Acute Lack of Obesity Jabs

Less than 10% of patients that would benefit from weight-loss injections including Wegovy have access to them, states the World Health Organization as it issues its first recommendations on the drugs.

Considering over a billion individuals worldwide now classified as obese, it is advocating for more widespread and fairer access to GLP-1 medication.

Based on estimates, in excess of 2,000,000,000 are projected to be living with obesity by 2030 if no action is taken.

"The new guidelines recognises that obesity is a chronic disease that can be treated with thorough and ongoing treatment," said the agency's head Tedros Adhanom Ghebreyesus.

Significant expense, constrained manufacturing, and logistical bottlenecks are significant hurdles to universal access to the jabs that can assist patients in reducing considerable body mass, says the agency.

GLP-1 Therapy Scarcity

Even under the current best projected case, the manufacturing of GLP-1 therapies might only reach approximately 100 million people – less than 10% of eligible patients, as stated by the WHO.

The advice calls on countries and companies to widen access, through strategies such as patent sharing.

A patent on a key compound – the primary component of a leading brand – is set to lapse in several nations in 2026.

How Obesity Injections Work

GLP-1 drugs replicate a body's own hormone to slow digestion, curb appetite and enhance satiety so individuals eat less.

Individuals commonly see weight reduction in the initial weeks of starting on the regular doses.

Studies suggests people may see weight return a year later of stopping the drug, when their normal food cravings return.

To be above a healthy weight increases your likelihood for experiencing diseases, like diabetes, heart disease, stroke, and certain malignancies.

Excess weight impacts individuals in countries worldwide and was linked to millions of fatalities worldwide in 2024, per the WHO.